Close

Capricor Therapeutics (CAPR) Announces Completion of Phase I/II HOPE-Duchenne Trial Enrollment

Go back to Capricor Therapeutics (CAPR) Announces Completion of Phase I/II HOPE-Duchenne Trial Enrollment